CD8A and melanoma: Treatment of B16F10 melanoma-bearing mice with the targeted siRNA-loaded LNPs in combination with doxorubicin boosted the chemo-immunotherapy efficacy, recruited CD8+ T cells, and reduced the number of tumor-promoting M2-like TAMs in the TME.